Obesity, Overweight
Conditions
Brief summary
The purpose of the study is to assess the weight loss in participants treated with commercially available semaglutide according to routine clinical practice at the discretion of the treating physician.
Interventions
DRUGSemaglutide
This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.
Sponsors
Novo Nordisk A/S
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Initiation of semaglutide for weight management during the study period. * Age more than or equal to (≥) 18 at treatment initiation * Baseline body mass index (BMI) ≥27 and less than (\<) 30 kilogram per meter square (kg/m\^2) with at least one weight-related comorbidity, or BMI ≥30 kg/m\^2. * Other inclusion criteria as defined in the protocol are applicable.
Exclusion criteria
* Prior use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) based medication or other obesity management medication (OMMs). * Bariatric surgery at baseline. * Diabetes at baseline. * Pregnancy at baseline.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in body weight | From index date (day 0) to week 68 (day 476) | Measured as kilogram (kg) |
| Proportion of individuals achieving a clinically meaningful weight loss | From index date (day 0) to week 68 (day 476) | Binary (yes/no): estimated ≥5% reduction from baseline body weight |
Countries
United Kingdom, United States
Contacts
STUDY_DIRECTORClinical Transparency (dept. 2834)
Novo Nordisk A/S
Outcome results
None listed